source
- Viking Therapeutics jumps 24% after Phase 1 obesity data, Longeveron falls 64% on mid-stage setbackIn September biotech stocks showed wide swings, with Viking Therapeutics gaining 24% and Longeveron dropping 64% as investors reacted to clinical data and trial setbacks. Viking reported Phase 1 r…
- Utah moves forward with AI-driven acne prescription pilot, Nolla Health to test autonomous drug prescribingUtah regulators announced a plan to allow an artificial intelligence product to evaluate patients and generate drug prescriptions without prior human review. Nolla Health, a startup, will launch a…